Cinda Securities released a research report on April 26 stating that it gave Anke Biotech (300009.SZ) a purchase rating. The main reasons for the rating include: 1) excellent performance in 2023, steady revenue growth in 24Q1; 2) the main business, biological products, maintained a continuous growth trend. (Mainichi Keizai Shimbun)
信达证券4月26日发布研报称，给予安科生物（300009.SZ）买入评级。评级理由主要包括：1）2023年业绩表现亮眼，24Q1收入稳健增长；2）主营业务生物制品保持持续增长态势。（每日经济新闻）
Cinda Securities released a research report on April 26 stating that it gave Anke Biotech (300009.SZ) a purchase rating. The main reasons for the rating include: 1) excellent performance in 2023, steady revenue growth in 24Q1; 2) the main business, biolog
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.